2025-12-17 - Analysis Report
Okay, here's a breakdown of Tempus AI (TEM) based on the data you've provided.

**TEM: Tempus AI Inc. - Overview: A technology company focused on precision medicine through data analysis and AI.**

## 1. Return Rate Comparison

*   **TEM Cumulative Return:** 21.58%
*   **VOO (S&P 500) Cumulative Return:** 29.03%
*   **Divergence:** 2.50
*   **Relative Divergence:** 37.50

**Analysis:** TEM has underperformed the S&P 500 (VOO) in terms of cumulative return. The divergence, while positive, is small. The relative divergence of 37.5 suggests the current divergence level is in the lower half of its historical range.

Looking at the provided Alpha, Beta analysis table:

*   **CAGR (2023-2025):** 22.0% This is a decent average annual growth rate.
*   **MDD (2023-2025):** 76.7% A very high Maximum Drawdown, indicating significant risk and volatility.
*   **Alpha (2023-2025):** -6.0% TEM has underperformed relative to its risk-adjusted benchmark.
*   **Beta (2023-2025):** 0.3 This indicates TEM is less volatile than the market, but that doesn't reflect the MDD.
*   **Cap(B):** 12.1B (Market Capitalization in Billions) A large-cap stock.

## 2. Recent Stock Price Fluctuations

*   **Current Close:** \$68.11
*   **Previous Close:** \$68.67
*   **Change:** -\$0.82
*   **5-day SMA:** \$71.26
*   **20-day SMA:** \$73.38
*   **60-day SMA:** \$80.90

**Analysis:** The stock price is currently trending downwards, as it's below all three moving averages. The 5-day SMA is below the 20-day SMA, which is below the 60-day SMA, confirming the downward trend.  The -\$0.82 change from the previous close reflects immediate fluctuation in the stock.

## 3. Index Indicators Analysis

*   **MRI (Market Risk Indicator):** 0.7 (Medium Investment)
*   **RSI:** 23.12 (Oversold)
*   **PPO:** -0.50
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (14 shares - Very Safe - MRI:0.90) Monthly invest 5.0% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** -0.7 (short-term decline)
*   **Expected Return (%):** Not Available (NaN)

**Analysis:**

*   The MRI of 0.7 suggests a medium investment recommendation based on overall market risk.
*   The RSI of 23.12 indicates the stock is oversold, potentially signaling a buying opportunity, although it could also indicate further downside potential.
*   The negative PPO (-0.50) indicates a negative momentum trend.
*   The Hybrid Signal recommends a "Buy" with full cash allocation.
*   The negative change in relative divergence over the past 20 days confirms a recent short-term decline.
*   The "Expected Return" is not available, which is a significant drawback. It's impossible to assess the long-term potential of the stock based on this data alone.

## 4. Recent News & Significant Events

The news headlines suggest a mixed outlook:

*   **FDA Clearance:** Positive news, potentially a growth catalyst.
*   **Analyst Opinions (Buy, Hold, or Sell):** Indicates some uncertainty or disagreement about the stock's future.
*   **Shares Acquired by Venture Visionary Partners LLC:** Generally positive, suggesting confidence in the company's prospects.
*   **Growth Catalysts Ahead:**  Positive signal.

## 4-2. Analyst Opinions

*   **Consensus:** Buy (Mean: 2.14)
*   **Target Price:** Average target price of \$90.17, suggesting significant upside potential from the current price of \$68.11.
*   **Recent Rating Changes:** Not provided.

**Analysis:** The analyst consensus points towards a positive outlook, with a "Buy" recommendation and a substantial target price. However, the lack of recent rating changes limits the usefulness of this information.

## 5. Comprehensive Analysis

Tempus AI (TEM) presents a mixed investment picture.

**Positive aspects:**

*   **FDA Clearance:** A significant development that could drive growth.
*   **Acquisition of shares by Venture Visionary Partners LLC:** Infers confidence in the company.
*   **Analyst Consensus:** A "Buy" recommendation and a target price significantly above the current market price.

**Negative aspects:**

*   **Underperformance vs. S&P 500:** TEM has not kept pace with the broader market.
*   **High Volatility:** The Maximum Drawdown (MDD) of 76.7% indicates significant price swings and risk.
*   **Downward Price Trend:** The stock is currently trading below its key moving averages.
*   **No expected return:** Cannot evaluate long-term investment returns from this data.

**Overall:** TEM appears to be a high-risk, high-reward investment. The company has potential growth catalysts (FDA clearance), but it also faces significant challenges (underperformance, high volatility, recent downward price trend). The analyst recommendations and target prices suggest potential upside, but the lack of historical data make it difficult to be more conclusive. The mixed news headlines further highlight the uncertainty surrounding the stock.

**Recommendation:** Before investing, you should:

*   **Investigate the reasons for the high volatility (MDD).**
*   **Understand the specifics of the FDA clearance** and its potential impact on revenue.
*   **Carefully evaluate your risk tolerance** given the stock's historical price swings.
*   **Review the company's financials**


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.